by Kinnate | Sep 9, 2020 | News
Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board Laurie Smaldone Alsup, M.D. also joins as a board member SAN DIEGO, Calif.— September 9, 2020 — Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small...
by Kinnate | Aug 26, 2020 | News
Kinnate Biopharma Closes $98 Million Series C Financing Proceeds will be used to scale programs focused on advancing the company’s portfolio of kinase inhibitors into clinical testing next year SAN DIEGO, Calif.— August 26, 2020 — Kinnate Biopharma Inc., a...
by Kinnate | Jul 8, 2020 | News
Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer Company further expands its leadership team with the appointment of 20-year Pfizer veteran Dr. Robert Kania, as Senior Vice President, Drug Discovery SAN DIEGO, Calif.— July 8, 2020 — Kinnate...
by Kinnate Biopharma | May 27, 2020 | News
Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer Company further expands executive leadership with the appointment of Mark Meltz as Chief Operating Officer and General Counsel SAN DIEGO, Calif. — May 27, 2020 — Kinnate Biopharma Inc., a precision...
by Kinnate Biopharma | Dec 19, 2019 | News
Kinnate Biopharma Closes $74.5M Series B Financing New investors OrbiMed, Nextech Invest and Vida Ventures join existing investors Foresite Capital and Eshelman Ventures. Proceeds will be used to advance multiple precision oncology drug candidates into the clinic. SAN...
by Kinnate Biopharma | Apr 11, 2018 | News
Fount Therapeutics Secures $22M Series A Financing Fount Therapeutics secures $22 million Series A financing from Foresite Capital and Eshelman Ventures. The funds will establish multiple subsidiary R&D companies to develop treatments in various therapeutic areas....
Recent Comments